Search results
Author(s):
Cuilin Zhu
,
Xiaomeng Wang
,
Xiao Liu
,
et al
Added:
3 weeks ago
Author(s):
Juxerez Maria B Sulit
,
Armand Delo Tan
Added:
9 months ago
Author(s):
Added:
2 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
JoAnn Lindenfeld
Job title: Professor of Medicine
Author
Author(s):
Bambang Dwiputra
,
Ade Meidian Ambari
,
Dwita Rian Desandri
,
et al
Added:
1 year ago
Author(s):
Brian Lindman
Added:
9 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Author(s):
Harriette Van Spall
,
Udo Bavendiek
Added:
4 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study…
View more
Author(s):
Aqtab Mazhar Alias
,
Raja Ezman Raja Shariff
,
Norashikin Saidon
,
et al
Added:
1 year ago
Author(s):
Rofila Dita Karmia
,
Mefri Yanni
,
Yusrawati
,
et al
Added:
3 weeks ago